T. Okazaki, A. Maeda, H. Nishimura, T. Kurosaki, and T. Honjo, PD-1 immunor- 630 eceptor inhibits B cell receptor-mediated signaling by recruiting src homol- 631 ogy 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine, p.632
DOI : 10.1073/pnas.231486598
URL : http://www.pnas.org/content/98/24/13866.full.pdf

K. Sheppard, L. Fitz, J. Lee, C. Benander, J. George et al., PD-1 634 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta 635 signalosome and downstream signaling to PKCtheta, FEBS Lett, vol.636574, pp.37-41, 2004.

Y. Zhang, S. Huang, D. Gong, Y. Qin, and Q. Shen, Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer, Cellular and Molecular Immunology, vol.173, issue.5, pp.389-95, 2010.
DOI : 10.1128/JVI.77.8.4911-4927.2003

A. Gros, P. Robbins, X. Yao, Y. Li, S. Turcotte et al., PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors, Journal of Clinical Investigation, vol.124, issue.5, pp.2246-59, 2014.
DOI : 10.1172/JCI73639DS1
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4001555/pdf

A. Gros, M. Parkhurst, E. Tran, A. Pasetto, P. Robbins et al., Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients, Nature Medicine, vol.22, issue.4, pp.433-441, 2016.
DOI : 10.4049/jimmunol.1103020

P. Ott, F. Hodi, and C. Robert, CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients, Clinical Cancer Research, vol.19, issue.19, pp.5300-5309, 2013.
DOI : 10.1158/1078-0432.CCR-13-0143
URL : http://clincancerres.aacrjournals.org/content/clincanres/19/19/5300.full.pdf

M. Gubin, X. Zhang, H. Schuster, E. Caron, J. Ward et al., Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens, Nature, vol.102, issue.7528, pp.577-81, 2014.
DOI : 10.1073/pnas.0506580102
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279952/pdf

D. Le, J. Uram, H. Wang, B. Bartlett, H. Kemberling et al., PD-1 684 blockade in tumors with mismatch-repair deficiency, N Engl J Med, vol.685372, pp.2509-2529, 2015.

C. Linnemann, M. Van-buuren, L. Bies, E. Verdegaal, R. Schotte et al., High-throughput epitope discovery reveals frequent recognition 691 of neo-antigens by CD4þ T cells in human melanoma Cancer genome landscapes, Nat Med Science, vol.69021339, issue.692, pp.81-86, 2013.

B. Youngblood, K. Oestreich, S. Ha, J. Duraiswamy, R. Akondy et al., Chronic Virus Infection Enforces Demethylation of the Locus that Encodes PD-1 in Antigen-Specific CD8+ T Cells, Immunity, vol.35, issue.3, pp.400-412, 2011.
DOI : 10.1016/j.immuni.2011.06.015

B. Youngblood, A. Noto, F. Porichis, R. Akondy, Z. Ndhlovu et al., Cutting Edge: Prolonged Exposure to HIV Reinforces a Poised Epigenetic Program for PD-1 Expression in Virus-Specific CD8 T Cells, The Journal of Immunology, vol.191, issue.2, pp.540-544, 2013.
DOI : 10.4049/jimmunol.1203161

E. Ahn, B. Youngblood, J. Lee, J. Lee, S. Sarkar et al., ABSTRACT, Journal of Virology, vol.90, issue.19, pp.8934-8980, 2016.
DOI : 10.1128/JVI.00798-16

. Melan-a, MART-1-specific CD8 T cells: from thymus to tumor. Trends 707, Immunol, vol.23, pp.325-333, 2002.

A. Giacomo, Functional T cells targeting NY-ESO-1 or Melan-A are 713 predictive for survival of patients with distant melanoma metastasis, J Clin Oncol, vol.71430, pp.1835-1876, 2012.

A. Khammari, N. Labarriere, V. Vignard, J. Nguyen, and M. Pandolfino, Knol 716 AC, et al. Treatment of metastatic melanoma with autologous Melan-A/ 717 MART-1-specific cytotoxic T lymphocyte clones, J Invest Dermatol, vol.718129, pp.2835-2877, 2009.

V. Vignard, B. Lemercier, A. Lim, M. Pandolfino, Y. Guilloux et al., Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in 721 melanoma patients is followed by increased frequencies of additional 722

S. Simon, V. Vignard, L. Florenceau, B. Dreno, A. Khammari et al., PD-1 expression conditions T cell avidity within an antigen-specific repertoire, OncoImmunology, vol.6, issue.1, pp.1104448-726, 2016.
DOI : 10.1097/CJI.0b013e3181fad2b0
URL : https://hal.archives-ouvertes.fr/inserm-01280886

N. Labarriere, A. Fortun, A. Bellec, A. Khammari, B. Dreno et al., A full 727 GMP process to select and amplify epitope-specific T lymphocytes for 728 adoptive immunotherapy of metastatic melanoma 731 Improved endpoints for cancer immunotherapy trials, Clin Dev Immunol J Natl Cancer Inst, vol.7292013102, issue.732, pp.1388-97, 2010.

M. Bodinier, M. Peyrat, C. Tournay, F. Davodeau, F. Romagne et al., 734 et al. Efficient detection and immunomagnetic sorting of specific T cells 735 using multimers of MHC class I and peptide with reduced CD8 binding, p.736

R. Bouqui-e, A. Bonnin, K. Bernardeau, A. Khammari, B. Dreno et al., 738 et al. A fast and efficient HLA multimer-based sorting procedure 740 that induces little apoptosis to isolate clinical grade human tumor 741 specific T lymphocytes, Cancer Immunol Immunother, vol.58, pp.742-553, 2009.

J. Chauvin, O. Pagliano, J. Fourcade, Z. Sun, H. Wang et al., TIGIT and PD-1 impair tumor antigen???specific CD8+ T cells in melanoma patients, Journal of Clinical Investigation, vol.125, issue.5, pp.2046-58, 2015.
DOI : 10.1172/JCI80445DS1
URL : http://www.jci.org/articles/view/80445/files/pdf

Q. Ye, D. Song, M. Poussin, T. Yamamoto, A. Best et al., CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor, Clinical Cancer Research, vol.20, issue.1, pp.44-55, 2014.
DOI : 10.1158/1078-0432.CCR-13-0945
URL : http://clincancerres.aacrjournals.org/content/clincanres/20/1/44.full.pdf

D. Pietras, Anti-CTLA-4 therapy broadens the melanoma-reactive 764

T. Schumacher and R. Schreiber, Neoantigens in cancer immunotherapy, Science, vol.43, issue.D1, p.769
DOI : 10.1093/nar/gku1075

A. Huang, M. Postow, R. Orlowski, R. Mick, B. Bengsch et al., T-cell invigoration to tumour burden ratio associated with anti-PD-1 response, Nature, vol.29, issue.7652, pp.60-65, 2017.
DOI : 10.1038/nbt.1991
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554367/pdf

V. Lennerz, M. Fatho, C. Gentilini, R. Frye, A. Lifke et al., The response of autologous T cells to a human melanoma is dominated by mutated neoantigens, Proceedings of the National Academy of Sciences, vol.36, issue.4, pp.16013-16021, 2005.
DOI : 10.2174/1566524013363447